Tybost
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection. It is also a component of the single-tablet regimen Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate). Tybost has no inherent antiretroviral activity. It inhibits cytochrome P450 3A4, an enzyme that metabolizes drugs, including PIs. This enables enhanced pharmacokinetics of PIs, allowing decreased dosing and a reduction in adverse events.
Analyst Outlook
A failure to provide any clinical advantage over the current standard-of-care boosting agent Norvir (ritonavir; AbbVie) means that Tybost (cobicistat; Gilead) will struggle to compete as a standalone agent to be used in combination with protease inhibitors (PIs) or integrase inhibitors. Tybost’s best chance of commercial success is as a component of Gilead’s single-tablet regimens (STRs) Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and as a component of fixed-dose combinations (FDCs) with PIs.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Tybost : HIV
LIST OF FIGURES
11 Figure 1: Tybost for HIV-1 infection – SWOT analysis
11 Figure 2: Datamonitor Healthcare drug assessment summary of Tybost in HIV-1
12 Figure 3: Datamonitor Healthcare drug assessment summary of Tybost in HIV-1
LIST OF TABLES
4 Table 1: Tybost drug profile
6 Table 2: Tybost pivotal trial data in HIV-1 infection
9 Table 3: Tybost late-phase trial data in HIV-1 infection
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
D/C/F/TAF 
Sign up to the